VYXEOS is a Intravenous Injection, Powder, Lyophilized, For Suspension in the Human Prescription Drug category. It is labeled and distributed by Jazz Pharmaceuticals, Inc.. The primary component is Cytarabine; Daunorubicin.
Product ID | 68727-745_28c59550-ef14-423e-8cb2-cf4a38339cab |
NDC | 68727-745 |
Product Type | Human Prescription Drug |
Proprietary Name | VYXEOS |
Generic Name | (daunorubicin And Cytarabine) Liposome |
Dosage Form | Injection, Powder, Lyophilized, For Suspension |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2017-08-03 |
Marketing Category | NDA / NDA |
Application Number | NDA209401 |
Labeler Name | Jazz Pharmaceuticals, Inc. |
Substance Name | CYTARABINE; DAUNORUBICIN |
Active Ingredient Strength | 100 mg/20mL; mg/20mL |
Pharm Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC],Anthracycline Topoisomerase Inhibitor [EPC],Anthracyclines [CS],Topoisomerase Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2017-08-03 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA209401 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-08-03 |
Marketing Category | NDA |
Application Number | NDA209401 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-08-03 |
Marketing Category | NDA |
Application Number | NDA209401 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-08-03 |
Ingredient | Strength |
---|---|
CYTARABINE | 100 mg/20mL |
SPL SET ID: | 7ea701ce-e7d3-4349-a9c2-642a501d45c8 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
VYXEOS 88265407 not registered Live/Pending |
Celator Pharmaceuticals, Inc. 2019-01-17 |
VYXEOS 86460047 5350908 Live/Registered |
Celator Pharmaceuticals, Inc. 2014-11-20 |